3.76
1.62%
0.06
After Hours:
3.83
0.07
+1.86%
Marker Therapeutics Inc stock is traded at $3.76, with a volume of 85,606.
It is up +1.62% in the last 24 hours and up +34.29% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
See More
Previous Close:
$3.70
Open:
$3.84
24h Volume:
85,606
Relative Volume:
2.42
Market Cap:
$33.55M
Revenue:
-
Net Income/Loss:
$-8.24M
P/E Ratio:
-2.4103
EPS:
-1.56
Net Cash Flow:
$-16.44M
1W Performance:
-7.62%
1M Performance:
+34.29%
6M Performance:
-8.52%
1Y Performance:
+23.28%
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-25-21 | Initiated | Piper Sandler | Overweight |
Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
May-30-19 | Initiated | ROTH Capital | Buy |
Mar-01-19 | Initiated | Janney | Buy |
Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
US Penny Stocks To Consider In October 2024 - Simply Wall St
Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire
Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - India Shorts
Kids Marker Market to hit USD 257.4 million by 2032, says Global Market Insights Inc. - Yahoo Finance
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire UK
AML cell therapy trials to watch in 2024 targeting GvHD - Yahoo Finance
Markforged (NYSE:MKFG) Sees Unusually-High Trading Volume - Defense World
Top 3 Health Care Stocks That May Explode This Month - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
On Tuesday’s show: Medical 'Blind Spots' - WJCT NEWS
ProShare Advisors LLC Has $47.68 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - PR Newswire
ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Meiji Yasuda Asset Management Co Ltd. Has $580,000 Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Washington Journal: Dr. Marty Makary Discusses His Book "Blind Spots" & Health Care in the U.S. - C-SPAN
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
Hematopoietic Stem Cell Transplantation Global Market Report 2024 Size and Forecast - WhaTech
Edgestream Partners L.P. Invests $1.67 Million in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Moderna Inc [NASDAQ: MRNA] Sees Decrease in Stock Value - Knox Daily
Hematopoietic stem cell transplantation (HSCT) Market to See - openPR
Down 13% in 1 Day, Is Moderna Stock in Trouble? - The Motley Fool
Quest Partners LLC Trims Stock Position in Marsh & McLennan Companies, Inc. (NYSE:MMC) - MarketBeat
Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Parallel Advisors LLC Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Dr. Marty Makary Talks "Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health" - The Clay Travis & Buck Sexton Show
Acadian Asset Management LLC Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Dai ichi Life Insurance Company Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Wedbush Securities Inc. Invests $393,000 in First Trust NASDAQ BuyWrite Income ETF (NASDAQ:FTQI) - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Buy” from Analysts - Defense World
United Parks & Resorts Inc. (NYSE:PRKS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
Palisade Bio Reports Data Demonstrating PDE4B Expression in - GlobeNewswire
Short Interest in Solventum Co. (NYSE:SOLV) Drops By 17.8% - Defense World
VanEck Pharmaceutical ETF (NASDAQ:PPH) Short Interest Down 17.3% in August - Defense World
MYR Group Inc. (NASDAQ:MYRG) Short Interest Update - Defense World
Phillips 66 (NYSE:PSX) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Bank of New York Mellon Corp Acquires 36,810 Shares of SEI Investments (NASDAQ:SEIC) - Defense World
Anthem Blue Cross and Blue Shield unveils a new historic marker in Columbus - Yahoo Finance
Raymond James & Associates Has $10.59 Million Stock Holdings in InvescoBulletShares2033 Corporate Bond ETF (NASDAQ:BSCX) - Defense World
MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024 - MSN
Will APOLLO Study Of MT-601 In Lymphoma Make A Mark? - RTTNews
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study - MSN
Marker Therapeutics Awarded $2 Million Grant from NIH in - GlobeNewswire
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma - StockTitan
Breast Tissue Markers Market Size to be Worth USD 5.8 billion by 2034, Growing at CAGR of 8.3% | Exclusive Report by Transparency Market Research, Inc. - Yahoo Finance
NightHawk Changes Name To Scorpius Holdings - Contract Pharma
IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
(MRKR) Investment Report - Stock Traders Daily
Soligenix (NASDAQ:SNGX) & Marker Therapeutics (NASDAQ:MRKR) Head-To-Head Contrast - Defense World
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $40.60 - Defense World
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):